PeptideDB

Firivumab

CAS: 1443004-15-6 F: W:

Firivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA) antibody. Firivumab i
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity Firivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA) antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice[1][2][3].
Target IC50: 0.1-1.3 μg/mL (H1N1), 0.78 μg/mL (H2N2), 0.48-0.65 μg/mL (H5N1), 4.69 μg/mL (H6N1), 4.69 μg/mL (H6N2), 2.34 μg/mL (H8N4), 1.3 μg/mL (H8N8), 2.08 μg/mL (H9N2) and 20.83 μg/mL (H12N7)
In Vivo Firivumab (CT-P22; CT120; 7.5-30 mg/kg; 腹腔给药; 感染后 24 小时) 在 >15 mg/kg 治疗组中对 H1N1 病毒显示 100% 的保护,在 7.5 mg/kg 治疗组中显示 70% 的保护[1]。Firivumab (添加 7.5 mg/kg Firivumab 和 7.5 mg/kg CT149) 在 A/California/04/09 (H1N1) 处理的小鼠中表现出全面保护[1]。 Animal Model:
Name Firivumab
CAS 1443004-15-6
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Reference [1]. Kye Sook Yi, et al. Broader neutralization of CT-P27 against influenza A subtypes by combining two human monoclonal antibodies. PLoS One. 2020 Jul 29;15(7):e0236172. [2]. John H Beigel, et al. Influenza Therapeutics in Clinical Practice-Challenges and Recent Advances. Cold Spring Harb Perspect Med. 2021 Apr 1;11(4):a038463. [3]. Seung Suh Hong, et al. Composition comprising at least two influenza a virus-neutralizing-binding molecules. EP3011968A1.